The Latest Articles from Streetwise Reports


Tech Co. ‘Right at the Point of Breakout'

Contributed Opinion
  ()
BioLargo Inc. seemed to be very close to breaking out of its tight trading range on July 20, 2022, after remaining in the same place for a month. Expert Clive Maund goes over this update and his assessment of the company after this news.

Study Review Shows Greater Promise for Biopharma Co.'s Cough Treatment

Research Report
  ()
After Algernon Pharmaceuticals Inc.'s Ifenprodil treatment for chronic cough was reviewed in a Phase 2 analysis, analysts at Research Capital Corp. noted that it is maintaining its Speculative Buy rating on the company.

Patients in Algernon’s Phase 2a Study Show Improved Lung Capacity

  ()
One junior biotech company that attempts to treat current health problems with older previously approved drugs, recently completed a Phase 2 study that showed promise in the treatment of idiopathic pulmonary fibrosis (IPF) and chronic cough. It moved the small company a step closer to bringing the treatment to market.

Analyst Update

Additional Study Review Reveals Patients Coughed Much Less

  ()
A scientist at a junior biotech company recently conducted an additional review of the top line data from a Phase 2a study that used NP-120 to treat idiopathic pulmonary fibrosis (IPF) and chronic cough — only to learn that it treated chronic cough far better than first thought.

Biotech Co. Granted New Patent for Breast Cancer Vaccine

Research Report
  ()
Last Thursday, Anixa Biosciences Inc. announced that the USPTO granted an extension for the firm's patented breast cancer vaccine technology. H.C. Wainwright & Co. LLC advised that this action strengthens the company's IP portfolio and therefore it is reiterating its Buy rating on Anixa.

Cancer Co.'s Price Target Adjusted After Reverse Stock Split

Research Report
  ()
Late clinical-stage biopharmaceutical company Cellectar Biosciences Inc. very recently underwent a one for 10 reverse stock split. ROTH Capital Partners LLC advised that it has adjusted its forward projections for the firm and adjusted its 12-month price target to $40/share.

Radiotherapy Co. On-Track With Two Clinical Trials

Research Report
  ()
Plus Therapeutics Inc. is developing novel radiotherapy treatments for several rare cancer targets including glioblastoma and leptomeningeal metastases. H.C. Wainwright & Co. advised in a research note that it is reiterating its Buy rating on the company as it expects that upcoming data from two key trials for the firm's RNL-based treatments could provide a major catalyst for the stock in H2/22.

Medical Device Firm Maintains Growth Momentum in Q2/22

Research Report
  ()
electroCore Inc.'s Q2/22 and H1/22 revenues are up quarter over quarter and year over year, respectively, and the upward trend is expected to continue through year-end 2022, noted an H.C. Wainwright & Co. report.

Biotech Co.'s Phase 3 Trial First to Get Grant

  ()
A revenue-generating junior biotech company based in the U.K. has become the first public company to be approved for a government grant to fund most of a Phase 3 study exploring the use of psychedelics to treat Alcohol Use Disorder. It could be a catalyst for the share price.

Drug Repurposing Co. Provides Opportunity for High Rewards

Research Report
  ()
Vancouver-based pharmaceutical development firm Algernon Pharmaceuticals Inc. recently reported topline data from a Phase 2a trial of ifenprodil in IPF patients with chronic cough that met its endpoint and demonstrated promising initial efficacy. Research Capital Corp. advised that it is maintaining its CA$25.00/share price target and "Speculative Buy" rating on the company.

Trial Results Show New Drug Improves Dry Eye Symptoms

Research Report
  ()
These study data from Aldeyra Therapeutics Inc. solidified the therapeutic's path to filing a new drug application, potentially in Q3/22, noted an H.C. Wainwright & Co. report.

Biopharma Co. Looks to Expand New Drug Label Down the Road

Research Report
  ()
ScPharmaceuticals Inc. just released topline results from a Phase 2 pilot study supporting the drug developer that is pursuing the expansion of its new drug label, noted an H.C. Wainwright & Co. report.

Healthcare Co.’s Psychedelic-Assisted Treatments Have ‘Blockbuster Drug Potential’

Research Report
  ()
Psychedelic-assisted therapy has shown in a clinical trial that it can help patients with Alcohol Use Disorder (AUD) or alcoholism. One company hopes to bring its treatments to clinics throughout Europe and become the go-to standard of care for AUD.

Healthcare Co. Wants Share of $17.5B Addiction Treatment Industry

Research Report
  ()
One healthcare co. is currently rated a Buy and is making a push for a share of the $17.5-billion addiction treatment industry after a recent study showed its psychedelic-assisted psychotherapy treatment showed a significant decrease in alcohol use, noted a Maxim Group equity research report.

Analyst Sees 'Attractive Long-Term Economics' for Healthcare Co.

Research Report
  ()
One healthcare company with upcoming catalysts wants to take a share of the CA$6-billion alcoholism treatment market with its proprietary psychedelic-assisted psychotherapy treatments.

Pharma Looks To Improve Potential Psychedelic Stroke Drug

  ()
Can a psychedelic compound help you heal after a stroke? This biopharmaceutical company hopes it can and plans to start Phase 1 trials this September.

Three Analysts Like Healthcare Co.'s Upside

  ()
It is difficult to get three people to agree on anything, let alone three investment analysts. But that is precisely the case with one junior biotech company that has shown in a clinical trial that its ketamine-assisted therapy for alcohol use disorder (AUD) is three times more effective than the current standard of care.

New Drug Is Shown to Help Stopped or Reduced Bile Flow

Research Report
  ()
Albireo Pharma Inc.'s positive Phase 3 trial results indicate the medication would afford patients clinical and quality of life benefits, noted an H.C. Wainwright & Co. report.

Showing Results: 26 to 50 of 165 Prev Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts